000084343 001__ 84343
000084343 005__ 20210507081948.0
000084343 0247_ $$2doi$$a10.1177/0269881119856546
000084343 0248_ $$2sideral$$a113129
000084343 037__ $$aART-2019-113129
000084343 041__ $$aeng
000084343 100__ $$0(orcid)0000-0002-5797-3909$$aLatorre, Eva$$uUniversidad de Zaragoza
000084343 245__ $$aAlternative splicing in serotonergic system: Implications in neuropsychiatric disorders
000084343 260__ $$c2019
000084343 5060_ $$aAccess copy available to the general public$$fUnrestricted
000084343 5203_ $$aBackground: The serotonergic system is a key component of physiological brain function and is essential for proper neurological activity. Numerous neuropsychiatric disorders are associated with deregulation of the serotonergic system. Accordingly, many pharmacological treatments are focused on modulation of this system. While providing a promising line of therapeutic moderation, these approaches may be complicated due to the presence of alternative splicing events for key genes in this pathway. Alternative splicing is a co-transcriptional process by which different mRNA transcripts can be produced from the same gene. These different isoforms may have diverse activities and functions, and their relative balance is often critical for the maintenance of homeostasis. Alternative splicing greatly increases the production of proteins, augmenting cell plasticity, and provides an important control point for regulation of gene expression. Aim: The objective of this narrative review is to discuss the potential impact of alternative splicing of different components of the serotonergic system and speculate on their involvement in several neuropsychiatric disorders. Conclusions: The specific role of each isoform in disease and their relative activities in the signalling pathways involved are yet to be determined. We need to gain a better understanding of the basis of alternative isoforms of the serotonergic system in order to fully understand their impact and be able to develop new effective pharmacological isoform-specific targets.
000084343 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000084343 590__ $$a3.121$$b2019
000084343 591__ $$aCLINICAL NEUROLOGY$$b75 / 204 = 0.368$$c2019$$dQ2$$eT2
000084343 591__ $$aPSYCHIATRY$$b57 / 154 = 0.37$$c2019$$dQ2$$eT2
000084343 591__ $$aPHARMACOLOGY & PHARMACY$$b103 / 270 = 0.381$$c2019$$dQ2$$eT2
000084343 591__ $$aNEUROSCIENCES$$b126 / 271 = 0.465$$c2019$$dQ2$$eT2
000084343 592__ $$a1.342$$b2019
000084343 593__ $$aMedicine (miscellaneous)$$c2019$$dQ1
000084343 593__ $$aPsychiatry and Mental Health$$c2019$$dQ1
000084343 593__ $$aPharmacology (medical)$$c2019$$dQ1
000084343 593__ $$aPharmacology$$c2019$$dQ1
000084343 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/acceptedVersion
000084343 700__ $$0(orcid)0000-0003-4758-3998$$aMesonero, Jose Emilio$$uUniversidad de Zaragoza
000084343 700__ $$aHarries, Lorna W.
000084343 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000084343 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular
000084343 773__ $$g33, 11 (2019), 1352-1363$$pJ. psychopharmacol.$$tJOURNAL OF PSYCHOPHARMACOLOGY$$x0269-8811
000084343 8564_ $$s348572$$uhttps://zaguan.unizar.es/record/84343/files/texto_completo.pdf$$yPostprint
000084343 8564_ $$s73113$$uhttps://zaguan.unizar.es/record/84343/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000084343 909CO $$ooai:zaguan.unizar.es:84343$$particulos$$pdriver
000084343 951__ $$a2021-05-07-08:11:26
000084343 980__ $$aARTICLE